Dr Fonesca provides his final thoughts recapping data and findings presented at ASH 2023.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
An update was provided on sonrotoclax, a next-generation BCL2 inhibitor that may exceed venetoclax potency. Early data combining sonrotoclax and dexamethasone shows efficacy in relapsed/refractory multiple myeloma with a favorable toxicity profile. This is an exciting addition given challenges gaining regulatory approval for venetoclax despite its clear value. While this translocation in level 14 imperfectly predicts response, other biomarkers like BCL2 expression levels or BCL2/BCL2L1 ratios could identify responsive patients for BCL2 inhibition. Fonesca hopes sonrotoclax progresses to become the first FDA-approved drug in this class for myeloma.
Looking ahead, 2024 may reveal more around small molecules like BCL2 inhibitors and next-generation cereblon-binding agents. Earlier chimeric antigen receptor T-cell and bispecific antibody data could emerge, potentially transforming outcomes when combined. The recent promising data also warrants follow-up. Fonseca believes properly combining these modalities can achieve high minimal residual disease negativity rates and long-term disease control. While myeloma remains incurable, glimpses of potential cures are being seen that bring hope for the future.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More
T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need
April 30th 2024"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of Evidence-Based Oncology.
Read More
Interactive mHealth App Helped Improve Patients’ Lifestyle Habits After Undergoing PCI
April 29th 2024These lifestyle improvements included adherence to the Mediterranean diet, improved frequency of healthy food consumption, increased physical activity, and quitting smoking, among other factors.
Read More
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More
T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need
April 30th 2024"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of Evidence-Based Oncology.
Read More
Interactive mHealth App Helped Improve Patients’ Lifestyle Habits After Undergoing PCI
April 29th 2024These lifestyle improvements included adherence to the Mediterranean diet, improved frequency of healthy food consumption, increased physical activity, and quitting smoking, among other factors.
Read More
2 Commerce Drive
Cranbury, NJ 08512